The European Commission (EC) has approved an extension of the use of Dupixent (dupilumab) within the European Union (EU) to include patients aged 12 to 17 years old with moderate-to-severe atopic dermatitis, Sanofi announced in an Aug. 6, 2019 press statement.
With this approval, Dupixent,Original Article
